ClinicalTrials.gg
CompletedNCT02840461Updated Jun 2, 2020Results posted

Clinical Endpoint Study of Ivermectin 1% Cream

A Phase 3 interventional study of Ivermectin Cream, 1% and Placebo/Vehicle cream in Moderate to Severe Papulopustular Rosacea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
14th of 137
630 · median 78
Started
2016
with 7 others
Phase 3
32 of 145
none open now
Registered
82nd of 145
by date
Lead sponsor
5 of 145
Actavis Inc.

Among the 145 studies in Rosacea with a site in United States, this one is the 14th largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2016, is one of 32 in phase 3, and was the 82nd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.

03

Conditions studied

  • Moderate to Severe Papulopustular Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed that meets all criteria of current FDA regulations.
  2. Healthy male or non-pregnant, non-lactating female greater than or equal to 8 years of age with a clinical diagnosis of moderate to severe papulopustular rosacea, defined as the presence of:

    A total of 8 to 50 combined papules/pustules on the face, AND At least moderate erythema, AND Telangiectasia

  3. Patient has a baseline Investigator's Global Evaluation (IGE) score of 3 (moderate) or 4 (severe) for rosacea severity (See Appendix A).
  4. Females of child bearing potential must not be pregnant or lactating at Screening (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of must agree to the use of a reliable method of (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. If the female is using a hormonal contraceptive, the same product must be taken for 3 months prior to Visit 1 and must agree not to replace with some other hormonal contraceptives during the study. A sterile sexual partner is not considered an adequate form of birth control.

    All females will be considered to be of childbearing potential unless they: Are , defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause.

    Have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks before Screening. Tubal ligation will not be considered a surgically sterile method.

    Female patients of childbearing potential are defined as Women without prior hysterectomy of at least 4 weeks, or who have had any evidence of menses in the past 12 months.

    Females who have been amenorrhea for more than or equal to 12 months, but the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.

  5. Free from any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events.
  6. Willing to minimize external factors that might trigger rosacea flare-ups (e.g., extreme temperatures, aggressive astringents, known offending foods such as spicy foods and thermally hot foods and drinks, prolonged sun exposure, strong winds, alcoholic beverages, and emotional stress) within 24 hours before the Screening visit.
  7. Of any skin type or race, provided the skin pigmentation allows accurate evaluation of papulopustular rosacea.
  8. Willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, lactating or planning to become pregnant during the study period.
  2. Patient has mild facial rosacea (less than 8 inflammatory lesions on the face) or very severe rosacea (more than 50 inflammatory lesions).
  3. Patient has mild erythema.
  4. Patient has a baseline IGE score of 0, 1 or 2.
  5. Patient has a skin condition on the face that would interfere with the diagnosis or assessment of rosacea (e.g., dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, acne, steroid folliculitis, bacterial folliculitis).
  6. Patients with excessive facial hair, such as beards, sideburns, moustaches, etc., that would interfere with diagnosis or assessment of rosacea.
  7. Patients with tattoos or excessive facial scarring that, in the Investigator's opinion, may interfere with the evaluation of the patient's rosacea.
  8. Patients with active facial sunburn, peeling from sunburn, or patients that will be exposed to excessive sunlight during the study.
  9. Patient has significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation.
  10. Any patient (male or female) who has started, or changed hormonal therapy within 3 months of the baseline visit (this includes hormonal ). Patients who have been on stable hormone therapy for at least 3 months and whose therapy is considered unlikely to be changed for the duration of the study will be eligible.
  11. History of or allergy to study drug, or other ingredients of the formulation.
  12. Use within 6 months prior to baseline of oral retinoids (e.g., Accutane) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  13. Use for less than 3 months prior to baseline of estrogen- and/or progestin-containing oral, injectable, implant, or transdermal contraceptives; use of such therapy must remain constant throughout the study.
  14. Use within 1 month prior to baseline of 1) topical retinoids to the face, 2) systemic (e.g., oral or injectable) antibiotics known to have an impact on the severity of facial rosacea (e.g., containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim), 3) systemic steroids, 4) photodynamic therapy (including laser and other light therapies), or 6) cosmetic procedures (e.g., superficial chemical peels, exfoliation or microdermabrasion of the face).
  15. Use within 2 weeks prior to baseline of 1) topical corticosteroids, 2) topical antibiotics, 3) topical anti-inflammatory agents or 4) topical medications for rosacea (e.g., metronidazole, azelaic acid, sodium sulfacetamide, ivermectin) 5) drugs, 6) anticoagulant therapy.
  16. Use of any other topical products applied to the target site.
  17. Use of systemic corticosteroids. The use of inhaled corticosteroids up to less than 1mg per day is acceptable.
  18. Use of antipruritics, including antihistamines, within 24 hours of study visits.
  19. Patients who use make-up must have used the same brands/types for a minimum period of 14 days before study entry and must agree to not change brand or frequency of use throughout the study.
  20. Presence of carcinoid, pheochromocytoma, or other causes of systemic flushing.
  21. Presence of acne conglobata, acne fulminans, secondary acne or severe acne requiring systemic treatment.
  22. Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.
  23. Receipt of any drug as part of a research study within 30 days before dosing.
  24. Employees of the research center or Investigator.
  25. Patients who are illiterate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
630 participants (actual)

Study arms

  • Experimental
    Ivermectin Cream, 1%

    test product, manufactured by Actavis Laboratories UT, Inc.

    Drug: Ivermectin Cream, 1%

  • Active comparator
    SoolantraTM (ivermectin) Cream, 1%

    reference product, manufactured by Galderma Laboratories, L.P.

    Drug: Ivermectin Cream, 1%

  • Placebo comparator
    Placebo/Vehicle cream

    Placebo, manufactured by Actavis Laboratories UT, Inc.

    Drug: Placebo/Vehicle cream

Interventions

  • DrugIvermectin Cream, 1%
  • DrugPlacebo/Vehicle cream
06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.

    Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within \[80%, 125%\].

    Time frame: Baseline and 12 Weeks

Secondary outcomes

  1. The Percentage of Patients With a Clinical Response of "Success".

    The secondary endpoint was the percentage of patients with a clinical response of "success" using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.

    Time frame: Baseline to Week 12

07

Results

Posted Jun 2, 2020

Participant flow

Participant flow — Overall Study
MilestoneIvermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle Cream
Started259257114
Completed236235100
Not completed232214
Withdrew: Adverse event153
Withdrew: Lost to follow-up1076
Withdrew: Non-comliance with dosing requirements010
Withdrew: Protocol violation231
Withdrew: Withdrawal by subject1062
Withdrew: Worsening of symptom & kit error002

Outcome measures

PrimaryPercent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.

Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within \[80%, 125%\].

Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · percentage of change from baseline
Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.
percentage of change from baselineIvermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Vehicle Cream
Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.-64.87 ± 2.03-64.87 ± 2.03-55.04 ± 2.92
Statistical analysis
  • Ivermectin Cream, 1% vs SoolantraTM (Ivermectin) Cream, 1% · Mean difference (net): 103.51 · 90% CI 97.95 to 110.00
  • Ivermectin Cream, 1% vs Vehicle Cream · ANOVA · p = 0.0027 · Mean difference (net): -9.83 · 95% CI -16.24 to -3.42
  • SoolantraTM (Ivermectin) Cream, 1% vs Vehicle Cream · ANOVA · p = 0.0028 · Mean difference (net): -9.83 · 95% CI -16.25 to -3.40
SecondaryThe Percentage of Patients With a Clinical Response of "Success".

The secondary endpoint was the percentage of patients with a clinical response of "success" using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
The Percentage of Patients With a Clinical Response of "Success".
ParticipantsIvermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Vehicle Cream
The Percentage of Patients With a Clinical Response of "Success".11710845
Statistical analysis
  • Ivermectin Cream, 1% vs SoolantraTM (Ivermectin) Cream, 1% · Mean difference (net): 5.8 · 90% CI -2.7 to 14.2

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivermectin Cream, 1%0/259 (0%)0/259 (0%)18/259 (6.9%)
SoolantraTM (Ivermectin) Cream, 1%0/257 (0%)0/257 (0%)24/257 (9.3%)
Placebo/Vehicle Cream0/114 (0%)0/114 (0%)14/114 (12.3%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventIvermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle Cream
HeadacheNervous system disorders2/2593/2572/114
Dermatitis contactSkin and subcutaneous tissue disorders0/2592/2572/114
NasopharyngitisInfections and infestations3/2590/2570/114
Application site eczemaGeneral disorders0/2590/2571/114
Application site erythemaGeneral disorders0/2590/2571/114
Acute sinusitisInfections and infestations0/2590/2571/114
BronchitisInfections and infestations1/2590/2571/114
PnuemoniaInfections and infestations0/2590/2571/114
SinusitisInfections and infestations1/2590/2571/114
Upper respiratory tract infectionInfections and infestations0/2590/2571/114

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ivermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle CreamTotal
Mean51.8 ± 15.450.3 ± 15.051.1 ± 14.151.1 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)Ivermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle CreamTotal
Female18218285449
Male777529181
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ivermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle CreamTotal
Hispanic or Latino13613365334
Not Hispanic or Latino12312449296
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ivermectin Cream, 1%SoolantraTM (Ivermectin) Cream, 1%Placebo/Vehicle CreamTotal
American Indian or Alaska Native1001
Asian0404
Native Hawaiian or Other Pacific Islander0000
Black or African American2002
White253253114620
More than one race3003
Unknown or Not Reported0000
08

Study locations

1 site
  • Investigator site 1
    Arlington Heights, Illinois 60005, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Nov 2016, 5 months.

Results were first posted in Jun 2020, 3 years 7 months after primary completion.

Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2016
First posted
Jul 21, 2016
StartActual
Jun 2016
Primary completionActual
Nov 2016
CompletionActual
Dec 2016
Results first posted
Jun 2, 2020
Last update
Jun 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02840461
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Jul 21, 2016
Start date
Jun 2016
Primary completion
Nov 2016
Completion
Dec 2016
Results posted
Jun 2, 2020
Last update
Jun 2, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion